NuSkin raises guidance
This article was originally published in The Rose Sheet
Executive Summary
NuSkin President and CEO Truman Hunt says "very successful prelaunch of our flagship ageLOC skin-care system at our global distributor convention, as well as our anticipation that Japan will continue to see a small trend improvement in the fourth quarter," have compelled NuSkin to bump up its fourth-quarter revenue projections. Provo, Utah company now expects fourth-quarter revenue in the range of $360 mil. to $365 mil., representing a 4.9% to 5% increase from its original guidance, according to Nov. 17 release. Firm anticipates booking roughly $1.31 billion in sales for the year, and $1.37 to $1.4 billion in 2010, according to CFO Ritch Wood
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.